A Phase II, Prospective ,Multicenter Study Evaluating the Efficacy and Safety of Orelabrutinib Plus R-CHOP in Treatment-naïve Patients With Double Expression Diffuse Large B-cell Lymphoma
Status: Recruiting
Location: See all (2) locations...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 2
SUMMARY
This is a multicenter prospective single arm phase II study, and the purpose of this study is to evaluate the safety and efficacy of orelabrutinib combined with R-CHOP in the treatment of treatment-naïve patients with double expression DLBCL.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 70
Healthy Volunteers: f
View:
• Newly diagnosed Double Expression Diffuse Large B-cell Lymphoma
‣ Age 18-70 years
⁃ ECOG performance status 0-2
⁃ Ann Arbor stage II-IV
⁃ 8.Subjects who in line with the testing standard of the clinical trial laboratory
⁃ Life expectancy ≥ 3months
Locations
Other Locations
China
Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences
RECRUITING
Jinan
The First Ailliated Hospital of Nanchang University
RECRUITING
Nanchang
Contact Information
Primary
zengjun Li
zengjunli@163.com
13642138692
Backup
Dan Liu
13256139207
Time Frame
Start Date: 2023-06-01
Estimated Completion Date: 2026-12-30
Participants
Target number of participants: 31
Treatments
Experimental: orelabrutinib+R-CHOP
Related Therapeutic Areas
Sponsors
Collaborators: The First Affiliated Hospital of Nanchang University
Leads: Shandong Cancer Hospital and Institute